## First-Line Management of Moderate–Severe COPD with Exacerbation History **Key Point:** Patients with COPD GOLD stage 3–4 AND a history of exacerbations (≥2 in past year) require triple therapy (LABA + LAMA + ICS) to reduce exacerbation frequency, hospitalization, and mortality. **High-Yield:** GOLD 2023 Exacerbation-Based Strategy: - **0 exacerbations:** LABA or LAMA monotherapy - **≥1 exacerbation (moderate–severe disease):** LABA + ICS OR LAMA + LABA (dual therapy) - **≥2 exacerbations OR ≥1 severe exacerbation:** LABA + LAMA + ICS (triple therapy) — **preferred** ## Triple Therapy Rationale ```mermaid flowchart TD A[COPD patient with exacerbation history]:::outcome --> B{Number of exacerbations?}:::decision B -->|0 exacerbations| C[LABA or LAMA monotherapy]:::action B -->|1 moderate exacerbation| D[LABA + ICS or LAMA + LABA]:::action B -->|≥2 exacerbations or 1 severe| E[LABA + LAMA + ICS Triple Therapy]:::action E --> F[Reduces exacerbations by 25-40%]:::outcome E --> G[Improves FEV₁ and quality of life]:::outcome ``` ## Component Roles in Triple Therapy | Component | Mechanism | Benefit in Exacerbations | |---|---|---| | **LAMA** | M3 antagonist | Reduces mucus hypersecretion; superior exacerbation reduction | | **LABA** | β₂ agonist | Bronchodilation; synergistic with LAMA | | **ICS** | Anti-inflammatory | Reduces airway inflammation; prevents exacerbation triggers | **Clinical Pearl:** Triple therapy is the only regimen shown in RCTs (e.g., TRILOGY, TRINITY) to reduce exacerbation-related mortality in COPD. The combination is more effective than any dual therapy. **Warning:** Oral corticosteroids are NOT first-line maintenance therapy — they are reserved for acute exacerbation management and carry long-term toxicity (osteoporosis, infection, hyperglycemia). [cite:GOLD 2023 Report, Harrison 21e Ch 254]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.